IFNA2 and cancer: To our knowledge, the only head-to-head comparison of treatment for metastatic RCC with a targeted therapy (sunitinib) compared with IFN-α used the EQ-5D index and EQ-VAS scores, and the data were consistent with other findings using disease-specific instruments, including the Functional Assessment of Cancer Therapy-General, and the Functional Assessment of Cancer Therapy-Kidney Symptom Index-15 item (Cella et al, 2008).